evidence suggests that inflammatory mechanisms contribute significantly to the progression of Alzheimer's disease. Granulocyte colonystimulating factor (G-CSF) is an antiinflammatory immunomodulator, but the mechanism of its anti-inflammatory effect is unclear. This study was designed to investigate whether G-CSF could inhibit inflammation in a mouse model of Alzheimer's disease through an a7 nicotinic acetylcholine receptor (a7 nAChR) pathway. Mice transgenic for the V171I mutant amyloid precursor protein (APP) were injected subcutaneously with G-CSF 50 µg/kg per day or phosphatebuffered saline (PBS; control group) for 7 days, and wild-type C57/BL6 mice were injected with PBS daily for 7 days. Mice were killed on days 7, 14 and 28 after treatment began. Levels of a7 nAChR protein were significantly increased and levels of interleukin-1b, tumour necrosis factor-a and nuclear factor-kB (NF-kB) protein were significantly decreased in the brain of APP transgenic mice in response to G-CSF. Levels of a7 nAChR protein correlated negatively with NF-kB levels. It is concluded that G-CSF might attenuate inflammation by down-regulating NF-kB and up-regulating a7 nAChR in the brain of APP transgenic mice, indicating a potential new therapeutic approach to Alzheimer's disease.
Introduction
Alzheimer's disease is a progressive neurodegenerative disorder with clinical symptoms of progressive dementia. The major neuropathological hallmarks are lesions of senile plaques and neuron loss in H Jiang, CX Liu, JB Feng et al. G-CSF attenuates chronic neuroinflammation in the brain the brain. 1 These senile plaques consist mainly of a large amount of β-amyloid peptide (Aβ) and abundant neurofibrillary tangles. Chronic inflammation, activated by Aβ and neurofibrillary tangles, appears to be the main pathogenesis of Alzheimer's disease. 2 -4 Neuroinflammation is associated with progression of Alzheimer's disease. The inflammatory environment results in a cascade of events: the activation of autoimmunity, microglia and astrocytes, the expression of certain genes in patients with particular conditions, the release of inflammatory mediators and, eventually, neuron death. 5 To eliminate neuroinflammation, anti-inflammatory therapy might be expected to be an effective clinical treatment for Alzheimer's disease. Indeed, agents such as non-steroidal antiinflammatory drugs can reduce the incidence and progression of Alzheimer's disease, 6 and other anti-inflammatory therapies are being investigated.
Granulocyte colony-stimulating factor (G-CSF), a haematopoietic factor, is a stimulator of neutrophil differentiation, proliferation and function. It is used clinically to treat neutropenia. G-CSF has been reported to have antiapoptotic, anti-inflammatory, neurotrophic and angiogenic properties related to neuroprotection. 7, 8 G-CSF decreases levels of interleukin (IL)-1β, IL-6 and IL-8 in several conditions of central nervous system infection and stroke (ischaemia/reperfusion). 9 Administration of G-CSF can rescue cognitive abilities as a consequence of its anti-inflammatory effect in Alzheimer's disease and in mouse models of cerebral ischaemia, 5,10 -12 but the precise mechanism by which it reduces the secretion of proinflammatory cytokines remains unknown.
The transcription factor, nuclear factor-κB (NF-κB), is a crucial regulator of the induction of proinflammatory cytokines, including IL-1β and tumour necrosis factor-α (TNF-α). Decreased levels of NF-κB can attenuate chronic inflammatory disorders. 13 Nicotinic acetylcholine receptors (nAChRs) are a family of ligand-gated ion channels that are widely expressed in mammalian cells. They are composed of a diverse pentameric assembly of α-and βsubunits. The subtype α7 nAChR is one of the predominant nAChRs in the brain. It is extensively expressed in microglia, astrocytes and neurons, 14, 15 and plays a crucial role in modulating postsynaptic transmission. 16, 17 Moreover, α7 nAChR decreases the levels of inflammatory mediators, including TNF-α, IL-1β, IL-6 and IL-18, through a signal transducer and activator of transcription 3 (STAT3)-NF-κB cascade. 18, 19 Consistent with this finding, endotoxaemia α7 nAChR-knockout mice showed high levels of production of IL-1β and IL-6. 20 The release of TNF-α, IL-6 and IL-1β has been shown to be significantly reduced in NIH3T3-pIRES2-EGFP-α7 nAChR cells, which can stably overexpress α7 nAChR. 21 This finding highlights the key role of α7 nAChR as a regulator of neuroinflammation in the central and peripheral nervous systems.
The mechanism by which the antineuroinflammatory effects of G-CSF are generated in the central nervous system is not yet known. In a recent study with a mouse model transgenic for the V171I mutation of the amyloid precursor protein (APP), we demonstrated that G-CSF reduced the expression of proinflammatory cytokines and that the anti-inflammatory action of G-CSF may result from a decrease in NF-κB and an increase in α7-nAChR protein levels (unpublished data). The present study was designed to investigate the changes in levels of proinflammatory cytokines after G-CSF H Jiang, CX Liu, JB Feng et al. G-CSF attenuates chronic neuroinflammation in the brain treatment in the brain of this mouse model of Alzheimer's disease and to explore the pathological mechanisms of these changes.
Materials and methods

ANIMALS AND TREATMENT
For the mouse model, APP V717I transgenic mice (n = 72; 10 months old; weight 30 ± 10 g) with the major features of Alzheimer's disease pathology, including inflammatory processes and an increased number of senile plaques, 22 were obtained from the Institute of Experimental Animals, Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing, China). Wild-type mice (C57/BL6 black; n = 36; 10 months old; body weight 30 ± 10 g) were obtained from the Animal Experiment Centre of Shandong University (Jinan, China). Mice were housed with a standard 12-h light/12-h dark cycle and had free access to water and food. The experimental procedures were approved by the Ethics Commission for Experiments on Animals of Shandong University and were in accordance with international standards.
Three groups of mice were used, with 36 mice in each group: the G-CSF, control and wild-type groups. The G-CSF and control groups each consisted of 36 APP V717I transgenic mice and the wild-type group consisted of 36 C57/BL6 black mice. Mice in the G-CSF group were injected subcutaneously with a daily dose of 50 µg/kg of recombinant human G-CSF (Kirin Brewery, Tokyo, Japan) for 7 days. The control and wild-type animals were injected with 0.01 M phosphate-buffered saline (PBS), pH 7.4, in parallel with the G-CSF group. Twelve mice in each group were killed on each of days 7, 14 and 28 after the start (day 1) of the 7-day treatment period. Six mice in each group of 12 were anaesthetized and perfused with 4% paraformaldehyde in 0.01 M PBS. The excised paraformaldehyde-fixed brains containing the frontal lobe cortex were immersed in 25% sucrose solution for 3 -4 days at 4°C. The brains were then cut into 10-µm thick coronal sections. The serial sections were used for immunohistochemistry and immunofluorescence staining. The frontal lobes of the brains of the remaining six out of 12 mice in each group were dissected out and frozen in liquid nitrogen; these samples were then prepared for Western blot analysis and stored at −80°C.
IMMUNOHISTOCHEMISTRY
Frozen tissue sections containing the frontal lobe cortex were incubated in 3.0% hydrogen peroxide in 0.01 M PBS, pH 7.4, and washed three times in 0.01 M PBS before incubation in 5% goat serum for 1 h. The slides were then incubated with rabbit antihuman α7 nAChR polyclonal antibody (1:200 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4°C. After rinsing the slides three times with 0.01 M PBS, the signal was detected with a Dako ChemMate™ EnVision™ K5007 detection kit (Dako, Glostrup, Denmark) according to the manufacturer's instructions. Sections were then photographed with an Olympus BX51 fluorescence microscope equipped with an Olympus DP71 camera (Olympus, Tokyo, Japan). The photomicrographs were analysed with Image-Pro™ Plus software, version 6.0 (Cybernetics, Silver Spring, MD, USA).
IMMUNOFLUORESCENCE STAINING
Frozen sections containing the frontal lobe cortex were incubated with the following primary antibodies: goat antimouse TNF-α polyclonal antibody (1:300 dilution; Santa Cruz Biotechnology), rabbit antihuman IL-1β polyclonal antibody (1:500 dilution; Abcam, Cambridge, UK) or rabbit antimouse polyclonal antibody NF-κB p65 (1:80 H Jiang, CX Liu, JB Feng et al. G-CSF attenuates chronic neuroinflammation in the brain dilution; Abcam) overnight at 4°C. For NF-κB p65 analysis only, the sections were first permeabilized with 0.01 M PBS, pH 7.4, containing 1% Triton X-100 before being incubated with the primary antibody. For all antibodies, after rinsing three times with 0.01 M PBS, the sections were then incubated for 1 h at room temperature with antirabbit secondary CF555-conjugated phalloidin (red) antibody (1:1000 dilution; Biotium Inc., Hayward, CA, USA). After counterstaining the nucleus with mounting medium containing 4′,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA, USA), the sections were photographed by fluorescence microscopy using the equipment described in the previous section.
WESTERN BLOT ANALYSIS
Frontal lobe tissues were homogenized at 4°C in 0.01 M PBS (pH 7.4) containing protease inhibitors (final concentrations: 10 µg/ml soybean trypsin inhibitor, 10 µg/ml benzamidine, 0.005 U/ml aprotinin [trypsin inhibitor], 10 µg/ml leupeptin, 10 µg/ml pepstatin A, 5 µg/ml antipain, 0.2 mmol/l phenylmethylsulphonyl fluoride and 0.1 mmol/l ethylenediaminetetra-acetic acid). Each sample was homogenized with a Polytron ® homogenizer (Brinkmann Instruments, Westbury, NY, USA) at 0°C, then sonicated on ice with a cell disrupter with five pulses at a duty cycle of 40% and output of 3. The homogenates were centrifuged at 10 000 g for 15 min at 4°C. Proteins were then separated from the supernatant by sodium dodecyl sulphatepolyacrylamide gel electrophoresis (10%) and transferred electrophoretically onto a nitrocellulose membrane. The membrane was blocked with a solution of 0.1% Tween 20/0.01 M PBS (PBS-T) containing 5% fat-free milk for 1 h, then incubated with primary rabbit antihuman α7 nAChR polyclonal (1:300) and anti-β-actin (1:2000) antibodies (both from Santa Cruz Biotechnology) for 2 h at room temperature (25°C), and then washed three times for 10 min with PBS-T. The blot was re-incubated with horseradish peroxidase-conjugated secondary immunoglobulin G antibody (1:2000 dilution; Santa Cruz Biotechnology) for 1 h at room temperature (25°C). After three further 10min washes with PBS-T, an enhanced chemiluminescence detection kit (Amersham Biosciences, Freiburg, Germany) was used according to the manufacturer's instruction for immunodetection. The protein bands on the X-ray film were analysed with an image analyser (Alpha Innotech, San Leandro, CA, USA). Protein levels were measured in all samples using a modified Lowry protein assay kit (Pierce, Rockford, IL, USA) in a range of 4 -6 µg/µl to ensure that equivalent protein amounts were added to each well of the sodium dodecyl sulphate-polyacrylamide gel electrophoresis gels.
STATISTICAL ANALYSIS
All statistical analysis were carried out using the SPSS ® statistical package, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Results are expressed as mean ± SE. Multiple variable comparisons were examined by analysis of variance. Spearman correlation analysis was used to test for correlations between α7 nAChR and NF-κB expression. Statistical significance was set at P < 0.05.
Results
IL-1b, TNF-a AND NF-kB PROTEIN LEVELS
Immunofluorescence was used to measure levels of the proinflammatory cytokines, IL-1β and TNF-α, and of the transcription factor, NF-κB, in the frontal lobe cortex of the brains from APP V717I transgenic mice treated with or without G-CSF and from wild-H Jiang, CX Liu, JB Feng et al. G-CSF attenuates chronic neuroinflammation in the brain type C57/BL6 black mice. The relative immunofluorescence intensities for IL-1β and TNF-α protein were significantly lower in frontal lobe cortex tissue from APP V717I transgenic mice treated with G-CSF than in untreated mice (controls) at 14 days (P < 0.01 for both IL-1β and TNF-α) and 28 days (P < 0.05 for IL-1β; P < 0.001 for TNF-α) after the start of the 7-day treatment period (Figs 1A  and 1B) . Thus, proinflammatory cytokine protein levels were markedly reduced in the APP V717I transgenic mouse brain after G-CSF administration. The relative immunofluorescence intensities for IL-1β and TNF-α protein in the frontal lobe cortex tissue of the wild type group of mice were significantly lower than in untreated mice (controls) at 7 days (P < 0.01 for both 1L-1β and TNF-α), 14 days (P < 0.001 for both IL-1β and TNF-α) and 28 days (P < 0.001 for both IL-1β and TNF-α) after the start of the 7-day treatment period (Figs 1A and 1B) . The relative immunofluorescence intensities for NF-κB protein were significantly lower in the frontal lobe cortex tissue of G-CSF-treated APP V717I transgenic mice than in tissue from untreated control transgenic mice at 7, 14 and 28 days after the start of the 7-day treatment period (P < 0.05; Fig. 1C ). Levels of NF-κB were significantly lower in the wildtype group than in the control group at all three time-points (P < 0.001).
LEVELS OF a7 NACHR PROTEIN
Western blot analysis showed that levels of α7 nAChR protein in the frontal lobe cortex tissue of APP V717I transgenic mice were significantly higher in mice treated with G-CSF compared with the untreated control group at 7, 14 and 28 days after the start of treatment (P < 0.001; Fig. 1D ). Levels in the wild-type group were also significantly higher than in the control group at the three timepoints (P < 0.01; Fig. 1D ). Immunohisto-chemical staining demonstrated that levels of α7 nAChR protein in the cortex were significantly higher in the G-CSF treatment group than in the control group at each of the three time points (P < 0.001); α7 nAChR protein levels peaked at 28 days in the G-CSF and control groups (Fig. 1E ). In addition, α7 nAChR protein levels were significantly lower in the wild-type group than in the control group at all three time points (P < 0.01).
CORRELATION BETWEEN a7 NACHR AND NF-kB LEVELS
Spearman correlation analysis revealed a significant inverse correlation between the levels of α7 nAChR and NF-κB on days 7 (r = −0.73, P = 0.007), 14 (r = −0.83, P = 0.008) and 28 (r = −0.89, P = 0.02).
Discussion
The present study investigated the changes in proinflammatory cytokines after treatment with G-CSF in the brain of Alzheimer's disease model mice and explored the pathological mechanisms underlying these changes. Protein levels of the proinflammatory cytokines, TNF-α and IL-1β, were significantly decreased in the brains of G-CSF-treated APP V717I transgenic mice compared with untreated control transgenic mice. Previous studies have shown that increased expression of proinflammatory cytokines, such as TNF-α and IL-1β, is a marker of immune and inflammatory reactions in the brain. 23, 24 Animal studies have shown G-CSF to be an anti-inflammatory immunomodulator, which reduces inflammatory activity by inhibiting the production or activity of the main inflammatory mediators, including IL-1, TNF-α and interferon-γ. 5, 25, 26 Thus, we speculated that neuroinflammation in the mouse brain with Alzheimer's disease might be effectively inhibited by G-CSF and we H Jiang, CX Liu, JB Feng et al. G-CSF attenuates chronic neuroinflammation in the brain F FI IG GU UR RE E 1 1: : Quantitative immunofluorescence detection of (A) proinflammatory cytokine interleukin 1β (IL-1β) protein levels, (B) proinflammatory cytokine tumour necrosis factor-α (TNF-α) protein levels, (C) nuclear factor κB (NF-κB) protein levels, (D) Western blot analysis of α7 nicotinic acetylcholine receptor (α7 nAChR) protein levels, and (E) immunohistochemistry detection of α7 nicotinic acetylcholine receptor (α7 nAChR) protein levels in the brain cortex of amyloid precursor protein V717I transgenic mice injected for 7 days with granulocyte colony-stimulating factor (G-CSF; 50 µg/kg per day) or phosphate-buffered saline (PBS; control), and in wild-type C57/BL6 black mice injected with PBS (mean ± SE relative to the control group at day 7 after the start of treatment [100%]; n = 6 mice per group on each day; *P < 0.05, **P < 0.01, ***P < 0.001 versus control) Levels of the transcription factor, NF-κB, were decreased in the brains of APP transgenic mice treated with G-CSF compared with control transgenic mice. This transcription factor has a dual role in promoting the survival of neurons and causing neurodegeneration by inducing the release of inflammatory mediators in glial cells. 27 The NF-κB pathway can be suppressed by an α7 nAChR-mediated nicotinic anti-inflammatory pathway. 28, 29 The present study demonstrated that G-CSF was able to down-regulate NF-κB and up-regulate α7 nAChR in the brain of Alzheimer's disease model mice. A previous study by Wang et al. 20 showed that α7 nAChR is essential for inhibiting inflammatory cytokine synthesis by the cholinergic anti-inflammatory pathway. They reported that electrical stimulation of the vagus nerve efficiently inhibited macrophage TNF synthesis and release in wild-type mice but not in α7 nAChRdeficient mice, thereby confirming that α7 nAChR is crucial in the inhibition of TNF release by acetylcholine. Thus, α7 nAChR might be the key receptor in the G-CSFrelated anti-inflammatory process in the Alzheimer's disease mouse model. The exact mechanism by which G-CSF upregulates α7 nAChR expression remains to be clarified.
In conclusion, the present study suggests that G-CSF significantly attenuates the expression of proinflammatory cytokines by up-regulating α7 nAChR in the brain of APP V717I transgenic mice. Thus, it may be worthwhile exploring G-CSF as a potential therapy for Alzheimer's disease.
